Our Take
Ionis is banking on first-mover advantage in a three-million-patient market, but competing ASO therapies are already in Phase III trials and could narrow the window significantly.
Why it matters
This is Ionis's inflection point from a rare-disease specialist to a primary-care player. Investors and competitors are watching whether the company can defend market share against incoming therapies and convert a large patient population into sustainable revenue.
Do this week
Cardiologists and lipidologists: review the CORE and CORE2 trial data in NEJM and audit your current sHTG patient management against the 72% triglyceride reduction and pancreatitis event reduction before deciding on Tryngolza positioning in your clinic.
FDA approves Tryngolza for severe hypertriglyceridemia
The US Food and Drug Administration approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (sHTG). The approval expands the drug's label beyond its original indication for familial chylomicronemia syndrome, a rare form of sHTG.
Tryngolza is the only approved targeted medication shown to improve pancreatitis outcomes in sHTG patients (per Ionis). The drug is an apoC-III antisense oligonucleotide that blocks apolipoprotein C-III production, enabling triglyceride clearance. It is self-administered once monthly via autoinjector.
The approval rests on Phase III CORE and CORE2 trials published in The New England Journal of Medicine. In the studies, Tryngolza cut fasting triglyceride levels by up to 72% compared to placebo at six months, with benefits sustained at one year. The drug reduced acute pancreatitis events by up to 91% (trial-reported). Eighty-six percent of treated patients achieved triglyceride levels below 500 mg/dL, a threshold for reducing pancreatitis risk.
Ionis has forecast $2 billion in peak sales for Tryngolza (company-reported), with GlobalData predicting $1.7 billion in global sales by 2032 (analyst estimate). CEO Brett Monia stated the approval marks Ionis's first blockbuster from a wholly owned product, positioning the company to expand beyond its prior reliance on partnership revenue.
First-mover advantage faces imminent pressure
Approximately three million people in the US have sHTG, with one million at high risk of complications. This is a material market far larger than the rare diseases Ionis has traditionally served. Tryngolza's monopoly on the sHTG indication is real but temporary.
Arrowhead's plozasiran, a competing GalNAc-ASO, is expected to report Phase III trial results (SHASTA-3 and SHASTA-4) in Q3 2025. Citi analysts note that near-term competitor data pose "an incremental hurdle to Ionis sentiment," though they credit Tryngolza's first-mover positioning. The window for uncontested market share is measured in quarters, not years.
Ionis is also responsible for launching Dawnzera (donidalorsen) for hereditary angioedema, meaning the company is executing two independent commercial campaigns simultaneously. Execution risk on the rarer indication is lower; execution risk on a three-million-patient population is material.
What clinicians should verify before adoption
The CORE and CORE2 trials were designed to enroll patients with elevated triglycerides despite prior therapy. Review the inclusion criteria, baseline triglyceride levels, and use of concomitant therapies to assess whether your patient population maps to trial participants. The 72% reduction is a median or mean; individual response variance matters for counseling.
Assess the pancreatitis event rate in your sHTG cohort. The 91% reduction in acute pancreatitis events is compelling, but absolute event rates in the trial arms determine clinical impact. A 5% baseline event rate reduced to 0.45% is different from a 20% baseline reduced to 1.8%.
Confirm pricing and insurance coverage once formularies update. Ionis's commercial infrastructure has succeeded in rare diseases. Adoption at scale in primary care depends on reimbursement, patient adherence to monthly injection, and durability of benefit in real-world populations outside trial settings.